Towards a blood-based diagnostic panel for bipolar disorder

• Verfasst von: Haenisch, Frieder [VerfasserIn]
• Verfasst von: Leweke, F. Markus [VerfasserIn]
• Titel: Towards a blood-based diagnostic panel for bipolar disorder
• Verf.angabe: Frieder Haenisch, Jason D. Cooper, Andreas Reif, Sarah Kittel-Schneider, Johann Steiner, F. Markus Leweke, Matthias Rothermundt, Nico J.M. van Beveren, Benedicto Crespo-Facorro, David W. Niebuhr, David N. Cowan, Natalya S. Weber, Robert H. Yolken, Brenda W.J.H. Penninx, Sabine Bahn
• Jahr: 2016
• Jahr des Originals: 2015
• Umfang: 9 S.
• Fussnoten: Gesehen am 28.01.2019 ; Available online 13 October 2015
• Titel Quelle: Enthalten in: Brain, behavior and immunity
• Ort Quelle: Orlando, Fla. [u.a.] : Elsevier, 1987
• Jahr Quelle: 2016
• Band/Heft Quelle: 52(2016), Seite 49-57
• ISSN Quelle: 1090-2139
• DOI: doi:10.1016/j.bbi.2015.10.001
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarker
• Sach-SW: Bipolar disorder
• Sach-SW: Diagnostic test
• Sach-SW: Differential diagnosis
• Sach-SW: Multiplex immunoassay
• K10plus-PPN: 1586649027

Abstract

Background: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment. We investigated the utility of a biomarker panel as a diagnostic test for BD. Methods and findings: We performed a meta-analysis of eight case-control studies to define a diagnostic biomarker panel for BD. After validating the panel on established BD patients, we applied it to undiagnosed BD patients. We analysed 249 BD, 122 pre-diagnostic BD, 75 pre-diagnostic schizophrenia and 90 first onset major depression disorder (MDD) patients and 371 controls. The biomarker panel was identified using ten-fold cross-validation with lasso regression applied to the 87 analytes available across the meta-analysis studies. We identified 20 protein analytes with excellent predictive performance [area under the curve (AUC)⩾0.90]. Importantly, the panel had a good predictive performance (AUC 0.84) to differentiate 12 misdiagnosed BD patients from 90 first onset MDD patients, and a fair to good predictive performance (AUC 0.79) to differentiate between 110 pre-diagnostic BD patients and 184 controls. We also demonstrated the disease specificity of the panel. Conclusions: An early and accurate diagnosis has the potential to delay or even prevent the onset of BD. This study demonstrates the potential utility of a biomarker panel as a diagnostic test for BD.